Generation of alloreactive T-cells in-vitro for cellular therapy

Mei Shao, Sherif Farag, Jeffrey Chalmers

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Allogeneic stem cell transplantation is the only curative option for numerous patients with hematological malignancies such as chronic leukemia and non-hodgkin's lymphoma. However, Graftversus-host disease (GVHD) caused by a subset of the T cell population, alloreactive T cells. GVHD is the major cause of mortality and limitations to the use of allogeneic stem cell transplantation. CD25 and CD69 are the most commonly used activation surface markers for the differentiation and depletion of alloreactive T cells; however, it has been reported that there is still relatively high, residual alloreactivity in cell suspensions after CD25+ and CD69+ T cell depletion. The purpose of this study is to optimize the generation of alloreactive T cells in vitro and select the optimum combination of the surface markers to represent alloreactive T cells. In this study, supported by the National Cancer Institute, we choose eight potential surface markers that are reported to appear on the activated T cells: CD25, CD69, CD71, OX40, CD38, CD152, CD122 and HLA-DR. In order to optimize the generation of alloreactive T cells, mature dendritic cells were used to stimulate the activation of alloreactive T cells in vitro. The inclusion of these dendric cells significantly increased the expression of these alloreactive surface markers on the T cells. A nine-parameter, flow cytometry system, BD FACS Aria, was used to assess the co-expression of these surface markers on alloreactive T cells. The immuno-function of cell subsets expressing different activation surface markers was determined by a cell proliferation assay. The optimum combination of activation surface markers for alloreactive T cells was determined on the basis of expression level and functional significance.

Original languageEnglish
Title of host publicationAIChE Annual Meeting, Conference Proceedings
Pages8690
Number of pages1
StatePublished - 2005
Externally publishedYes
Event05AIChE: 2005 AIChE Annual Meeting and Fall Showcase - Cincinnati, OH, United States
Duration: Oct 30 2005Nov 4 2005

Other

Other05AIChE: 2005 AIChE Annual Meeting and Fall Showcase
CountryUnited States
CityCincinnati, OH
Period10/30/0511/4/05

Fingerprint

T-cells
Chemical activation
Stem cells
Flow cytometry
Cell proliferation
Surface potential
Set theory
Assays

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Shao, M., Farag, S., & Chalmers, J. (2005). Generation of alloreactive T-cells in-vitro for cellular therapy. In AIChE Annual Meeting, Conference Proceedings (pp. 8690)

Generation of alloreactive T-cells in-vitro for cellular therapy. / Shao, Mei; Farag, Sherif; Chalmers, Jeffrey.

AIChE Annual Meeting, Conference Proceedings. 2005. p. 8690.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Shao, M, Farag, S & Chalmers, J 2005, Generation of alloreactive T-cells in-vitro for cellular therapy. in AIChE Annual Meeting, Conference Proceedings. pp. 8690, 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States, 10/30/05.
Shao M, Farag S, Chalmers J. Generation of alloreactive T-cells in-vitro for cellular therapy. In AIChE Annual Meeting, Conference Proceedings. 2005. p. 8690
Shao, Mei ; Farag, Sherif ; Chalmers, Jeffrey. / Generation of alloreactive T-cells in-vitro for cellular therapy. AIChE Annual Meeting, Conference Proceedings. 2005. pp. 8690
@inproceedings{b9eb235cacb34275b97c766c0c7e1a2b,
title = "Generation of alloreactive T-cells in-vitro for cellular therapy",
abstract = "Allogeneic stem cell transplantation is the only curative option for numerous patients with hematological malignancies such as chronic leukemia and non-hodgkin's lymphoma. However, Graftversus-host disease (GVHD) caused by a subset of the T cell population, alloreactive T cells. GVHD is the major cause of mortality and limitations to the use of allogeneic stem cell transplantation. CD25 and CD69 are the most commonly used activation surface markers for the differentiation and depletion of alloreactive T cells; however, it has been reported that there is still relatively high, residual alloreactivity in cell suspensions after CD25+ and CD69+ T cell depletion. The purpose of this study is to optimize the generation of alloreactive T cells in vitro and select the optimum combination of the surface markers to represent alloreactive T cells. In this study, supported by the National Cancer Institute, we choose eight potential surface markers that are reported to appear on the activated T cells: CD25, CD69, CD71, OX40, CD38, CD152, CD122 and HLA-DR. In order to optimize the generation of alloreactive T cells, mature dendritic cells were used to stimulate the activation of alloreactive T cells in vitro. The inclusion of these dendric cells significantly increased the expression of these alloreactive surface markers on the T cells. A nine-parameter, flow cytometry system, BD FACS Aria, was used to assess the co-expression of these surface markers on alloreactive T cells. The immuno-function of cell subsets expressing different activation surface markers was determined by a cell proliferation assay. The optimum combination of activation surface markers for alloreactive T cells was determined on the basis of expression level and functional significance.",
author = "Mei Shao and Sherif Farag and Jeffrey Chalmers",
year = "2005",
language = "English",
pages = "8690",
booktitle = "AIChE Annual Meeting, Conference Proceedings",

}

TY - GEN

T1 - Generation of alloreactive T-cells in-vitro for cellular therapy

AU - Shao, Mei

AU - Farag, Sherif

AU - Chalmers, Jeffrey

PY - 2005

Y1 - 2005

N2 - Allogeneic stem cell transplantation is the only curative option for numerous patients with hematological malignancies such as chronic leukemia and non-hodgkin's lymphoma. However, Graftversus-host disease (GVHD) caused by a subset of the T cell population, alloreactive T cells. GVHD is the major cause of mortality and limitations to the use of allogeneic stem cell transplantation. CD25 and CD69 are the most commonly used activation surface markers for the differentiation and depletion of alloreactive T cells; however, it has been reported that there is still relatively high, residual alloreactivity in cell suspensions after CD25+ and CD69+ T cell depletion. The purpose of this study is to optimize the generation of alloreactive T cells in vitro and select the optimum combination of the surface markers to represent alloreactive T cells. In this study, supported by the National Cancer Institute, we choose eight potential surface markers that are reported to appear on the activated T cells: CD25, CD69, CD71, OX40, CD38, CD152, CD122 and HLA-DR. In order to optimize the generation of alloreactive T cells, mature dendritic cells were used to stimulate the activation of alloreactive T cells in vitro. The inclusion of these dendric cells significantly increased the expression of these alloreactive surface markers on the T cells. A nine-parameter, flow cytometry system, BD FACS Aria, was used to assess the co-expression of these surface markers on alloreactive T cells. The immuno-function of cell subsets expressing different activation surface markers was determined by a cell proliferation assay. The optimum combination of activation surface markers for alloreactive T cells was determined on the basis of expression level and functional significance.

AB - Allogeneic stem cell transplantation is the only curative option for numerous patients with hematological malignancies such as chronic leukemia and non-hodgkin's lymphoma. However, Graftversus-host disease (GVHD) caused by a subset of the T cell population, alloreactive T cells. GVHD is the major cause of mortality and limitations to the use of allogeneic stem cell transplantation. CD25 and CD69 are the most commonly used activation surface markers for the differentiation and depletion of alloreactive T cells; however, it has been reported that there is still relatively high, residual alloreactivity in cell suspensions after CD25+ and CD69+ T cell depletion. The purpose of this study is to optimize the generation of alloreactive T cells in vitro and select the optimum combination of the surface markers to represent alloreactive T cells. In this study, supported by the National Cancer Institute, we choose eight potential surface markers that are reported to appear on the activated T cells: CD25, CD69, CD71, OX40, CD38, CD152, CD122 and HLA-DR. In order to optimize the generation of alloreactive T cells, mature dendritic cells were used to stimulate the activation of alloreactive T cells in vitro. The inclusion of these dendric cells significantly increased the expression of these alloreactive surface markers on the T cells. A nine-parameter, flow cytometry system, BD FACS Aria, was used to assess the co-expression of these surface markers on alloreactive T cells. The immuno-function of cell subsets expressing different activation surface markers was determined by a cell proliferation assay. The optimum combination of activation surface markers for alloreactive T cells was determined on the basis of expression level and functional significance.

UR - http://www.scopus.com/inward/record.url?scp=33645637049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645637049&partnerID=8YFLogxK

M3 - Conference contribution

SP - 8690

BT - AIChE Annual Meeting, Conference Proceedings

ER -